{rfName}
Ea

Indexed in

License and Use

Icono OpenAccess

Citations

83

Altmetrics

Analysis of institutional authors

Nicolas Arfelis, Josep MAuthor

Share

April 5, 2022
Publications
>
Review

Early intervention in psoriasis and immune-mediated inflammatory diseases: A hypothesis paper

Publicated to: Journal Of Dermatological Treatment. 26 (2): 103-112 - 2015-01-01 26(2), DOI: 10.3109/09546634.2014.880396

Authors: Girolomoni, G; Griffiths, CEM; Krueger, J; Nestle, FO; Nicolas, JF; Prinz, JC; Puig, L; Stahle, M; van de Kerkhof, PCM; Allez, M; Emery, P; Paul, C

Affiliations

Guys Hosp, Kings Coll London, St Johns Inst Dermatol, Sch Med,Div Genet & Mol Med, London SE1 9RT, England - Author
Hop Larrey, Dept Dermatol, F-31059 Toulouse, France - Author
Karolinska Inst, Dept Med, Unit Dermatol, Stockholm, Sweden - Author
Leeds Teaching Hosp NHS Trust, NIHR Leeds Musculoskeletal Biomed Res Unit, Leeds, W Yorkshire, England - Author
Radboud Univ Nijmegen, Med Ctr, Dept Dermatol, NL-6525 ED Nijmegen, Netherlands - Author
Rockefeller Univ, Invest Dermatol Lab, New York, NY 10021 USA - Author
Univ Autonoma Barcelona, Dept Dermatol, Hosp Santa Creu & St Pau, E-08193 Barcelona, Spain - Author
Univ Denis Diderot Paris 7, APHP, St Louis Hosp, Dept Gastroenterol, Paris, France - Author
Univ Leeds, Chapel Allerton Hosp, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England - Author
Univ Lyon, UFR Lyon Sud, INSERM, Dept Allergol & Clin Immunol,U851,IFR 128, Lyon, France - Author
Univ Manchester, Manchester Acad Hlth Sci Ctr, Salford Royal Hosp, Dermatol Ctr, Manchester, Lancs, England - Author
Univ Munich, Dept Dermatol, D-80539 Munich, Germany - Author
Univ Toulouse 3, F-31059 Toulouse, France - Author
Univ Verona, Sect Dermatol & Venereol, Dept Med, I-37100 Verona, Italy - Author
See more

Abstract

Psoriasis is an immune-mediated inflammatory disease (IMID) which may have a major impact on a patient's life, especially when the disease is moderate to severe. There is evidence that treatment of psoriasis during the first years is conservative and frequently based on topical agents which rarely clear lesions. Treatment with systemic agents including biologics is often undertaken only when topical agents have proved unsuitable, even in patients with moderate to severe disease. However, there is evidence that in other IMIDs (rheumatoid arthritis and Crohn's disease), targeted systemic treatment given early in the treatment pathway may improve long-term patient outcomes. We hypothesize that a patient-centered therapeutic approach, undertaken early in the psoriasis treatment pathway (early intervention) with the goal of complete clearance, may improve control of cutaneous symptoms and may also modify disease course and burden. Critical points to address when designing an early intervention study would include: the definition of psoriasis disease activity; patient selection; intervention selection; and dosing strategies.

Keywords

comorbiditiesearly interventionmanagementpathophysiologyChronic plaque psoriasisClinical remissionComorbiditiesCrohns-diseaseDouble-blindEarly interventionGenome-wide associationManagementMonoclonal-antibodyNecrosis-factor-alphaPathophysiologyPlasmacytoid dendritic cellsPsoriasisRheumatoid-arthritis patientsSusceptibility loci

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Journal Of Dermatological Treatment due to its progression and the good impact it has achieved in recent years, according to the agency Scopus (SJR), it has become a reference in its field. In the year of publication of the work, 2015, it was in position , thus managing to position itself as a Q1 (Primer Cuartil), in the category Dermatology.

From a relative perspective, and based on the normalized impact indicator calculated from World Citations provided by WoS (ESI, Clarivate), it yields a value for the citation normalization relative to the expected citation rate of: 1.15. This indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: ESI Nov 13, 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-12-16, the following number of citations:

  • WoS: 25

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-12-16:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 95.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 95 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 3.

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: France; Germany; Italy; Netherlands; Sweden; United Kingdom; United States of America.

Awards linked to the item

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article. Funding sources: Development of this article was supported by Janssen Pharmaceutica NV.